Insys Therapeutics to Present at 10th Annual Wells Fargo Healthcare Conference

(firmenpresse) - PHOENIX, AZ -- (Marketwired) -- 09/01/15 -- Insys Therapeutics, Inc. ("Insys" or "the Company") (NASDAQ: INSY) today announced that Michael Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will present at the 10th Annual Wells Fargo Healthcare Conference as follows:

Conference: Wednesday, September 9, 2015
Time: 8:50 a.m. EDT
Website:

The presentation will be webcast live at the aforementioned time and site as well as archived for 90 days thereafter, via the Company's website at , under the Investors Section.

Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. The Company recently submitted a New Drug Application to the U.S. Food and Drug Administration for Dronabinol Oral Solution, a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as synthetic pharmaceutical cannabidiol.

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 01.09.2015 - 12:00 Uhr
Sprache: Deutsch
News-ID 417183
Anzahl Zeichen: 0

contact information:
Town:

PHOENIX, AZ

Kategorie:

Drugs

Diese Pressemitteilung wurde bisher 178 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Insys Therapeutics to Present at 10th Annual Wells Fargo Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

Insys Therapeutics (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Insys Therapeutics Announces Its Naloxone Sublingual Spray Received Fast Track D ...

PHOENIX, AZ -- (Marketwired) -- 10/29/15 -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation to its ...

Insys Therapeutics Issues Statement on Its Use of Specialty Pharmacies ...

PHOENIX, AZ -- (Marketwired) -- 10/26/15 -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today issued a statement on the Company's use of specialty pharmacies:Insys distributes Subsys through both speci ...

Insys Therapeutics to Report Third Quarter 2015 Results ...

PHOENIX, AZ -- (Marketwired) -- 10/22/15 -- Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will release its financial results for the third quarter 2015 on Thursday, November 5, 2015, before the U.S. financial markets open. ...

Alle Meldungen von Insys Therapeutics